Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy) Pipeline Report 2016 - Global Review of 8 Companies & Drug Profiles - Research and Markets

DUBLIN--()--Research and Markets has announced the addition of the "Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy) - Pipeline Review, H1 2016" report to their offering.

This report provides comprehensive information on the therapeutic development for Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy) and special features on late-stage and discontinued projects.

The report enhances decision-making capabilities and helps to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Key Topics Covered:

  1. Introduction
  2. Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy) Overview
  3. Therapeutics Development
  4. Pipeline Products for Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy) - Overview
  5. Pipeline Products for Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy) - Comparative Analysis
  6. Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy) - Therapeutics under Development by Companies
  7. Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy) - Therapeutics under Investigation by Universities/Institutes
  8. Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy) Products Glance
  9. Late Stage Products
  10. Clinical Stage Products
  11. Early Stage Products
  12. Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy) - Products under Development by Companies
  13. Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy) - Products under Investigation by Universities/Institutes
  14. Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy) - Companies Involved in Therapeutics Development
  • Biscayne Pharmaceuticals, Inc.
  • GW Pharmaceuticals Plc
  • INSYS Therapeutics, Inc.
  • OPKO Health, Inc.
  • PTC Therapeutics, Inc.
  • Sage Therapeutics, Inc.
  • Xenon Pharmaceuticals Inc.
  • Zogenix, Inc.

For more information visit http://www.researchandmarkets.com/research/kdk78n/dravet_syndrome

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Central Nervous System Drugs

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Central Nervous System Drugs